GXV 002
Alternative Names: GXV-002Latest Information Update: 28 Jun 2026
At a glance
- Originator Takeda
- Developer GEXVal
- Class Cardiovascular therapies; Heart failure therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Heart failure
- No development reported Cardiomyopathies; Pulmonary arterial hypertension
Most Recent Events
- 28 Jun 2026 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in Japan
- 28 Jun 2026 No recent reports of development identified for research development in Cardiomyopathies in Japan
- 10 Jan 2024 Early research in Heart failure in Japan (unspecified route) before January 2024 (GEXVal pipeline, January 2024)